Clinical and pharmacological implications of time to treatment with interleukin-1 blockade in ST-segment elevation myocardial infarction

MG Del Buono, JI Damonte, F Moroni… - … of Pharmacology and …, 2023 - ASPET
Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been
shown to reduce the inflammatory response as well as prevent heart failure (HF) events in …
被引用次数：4 相关文章

Clinical and Pharmacological Implications of Time to Treatment with Interleukin-1 Blockade in ST-Segment Elevation Myocardial Infarction.

MG Del Buono, JI Damonte, F Moroni… - The Journal of …, 2023 - europepmc.org
Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been
shown to reduce the inflammatory response as well as prevent heart failure (HF) events in …

Clinical and Pharmacological Implications of Time to Treatment with Interleukin-1 Blockade in ST-Segment Elevation Myocardial Infarction

MG Del Buono, JI Damonte, F Moroni… - THE JOURNAL OF …, 2023 - iris.uniroma1.it
Abstract Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion
has been shown to reduce the inflammatory response as well as prevent heart failure (HF) …

Clinical and Pharmacological Implications of Time to Treatment with Interleukin-1 Blockade in ST-Segment Elevation Myocardial Infarction

MG Del Buono, JI Damonte… - The Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been
shown to reduce the inflammatory response as well as prevent heart failure (HF) events in …

Clinical and Pharmacological Implications of Time to Treatment with Interleukin-1 Blockade in ST-Segment Elevation Myocardial Infarction

MG Del Buono, JI DAMONTE, F Moroni… - … of Pharmacology and …, 2023 - ASPET
Interleukin-1 (IL-1) blockade with anakinra given within 12 hours from reperfusion has been
shown to reduce the inflammatory response as well as prevent heart failure (HF) events in …